SC
TGTX icon

Stephens Consulting’s TG Therapeutics TGTX Stock Holding History

Stephens Consulting’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-40
Closed -$1.58K – 1929
2025
Q1 		$1.58K Buy
+40
New +$1.35K ﹤0.01% 493

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Stephens Consulting's TGTX Position: Q2 2025 in Review

Stephens Consulting sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 40 shares — an estimated $1.58K sold.

Stephens Consulting first reported a position in TGTX in Q1 2025 and held it in 1 quarter. The position peaked at $1.58K in Q1 2025. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

  • Stephens Consulting reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stephens Consulting sold 40 TG Therapeutics shares in Q2 2025, an estimated $1.58K.
  • Stephens Consulting first reported a position in TG Therapeutics in Q1 2025 and held it in 1 quarter.
  • Stephens Consulting's TG Therapeutics position peaked at $1.58K in Q1 2025.
  • 356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.